Key result
In HIV-infected MSM, the seroconversion rate at week 48 was similar between three and two doses of HAV vaccine (77.8% vs 75.7%), both lower than in HIV-uninfected MSM receiving two doses (88.5%).
Why the study?
Does a three-dose hepatitis A vaccine regimen improve seroconversion rates compared to a two-dose regimen in HIV-infected men who have sex with men?
Population
582 men who have sex with men aged 18 to 40 years who were seronegative for HAV, including HIV-infected and…
Comparison
Three doses of hepatitis A virus vaccine given… vs Two doses of HAV vaccine given at weeks 0 and 24.
Design
Cohort
Follow-up
72 weeks
Authors
Loading...
Three-dose HAV vaccination does not improve seroconversion in HIV-infected MSM; leaves open optimal strategies to close the gap with uninfected controls.
Cohort (n=582)
Does a three-dose hepatitis A vaccine regimen improve seroconversion rates compared to a two-dose regimen in HIV-infected men who have sex with men?
Absolute Event Rate: 77.8% vs 75.7%
A three-dose hepatitis A vaccine regimen does not significantly improve seroconversion rates compared to a two-dose regimen in HIV-infected men who have sex with men, though higher CD4 counts and viral suppression predict better responses.
Tseng et al. (2012) conducted a cohort in HIV infection (n=582). Three doses of hepatitis A virus (HAV) vaccine vs. Two doses of HAV vaccine was evaluated on Seroconversion at week 48. In HIV-infected MSM, the seroconversion rate at week 48 was similar between three and two doses of HAV vaccine (77.8% vs 75.7%), both lower than in HIV-uninfected MSM receiving two doses (88.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: